MORE►
cancer
SMU Biology Professor Dr. Zhihao Wu [Photo: SMU]
SMU Professor Gets $1.8M NIH Award to Study How Bodies May Work to Repair Cells
by David Seeley | Sep 18, 2023
The award will help SMU biology professor Zhihao Wu determine if different "quality control pathways" in our bodies might be working together to repair damaged components in cells. The research could help lead to "new therapeutic targets" for hallmarks known to cause many human diseases, the university said.
by Lance Murray |
Aug 17, 2023
The 29 new grants approved by CPRIT's Oversight Committee include the first CPRIT Scholar award to Southern Methodist University in Dallas and state funding for Dallas' Baylor Research Institute to join a major National Cancer Institute study.
MORE►
by Lance Murray |
Mar 13, 2023
“Our researchers continue to push the envelope on developing a better understanding of cancer and new ways to help cancer patients in Texas and beyond,” said Center Director Carlos L. Arteaga, M.D.
MORE►
by Lance Murray |
Mar 9, 2023
The researchers discovered how healthy bacteria can escape the intestine, travel to lymph nodes and cancerous tumors elsewhere in the body, and boost the effectiveness of certain immunotherapy drugs. “Now we understand that mechanism much better and, in the future, hope to use this knowledge to better fight cancer," said UT Southwestern's Andrew Y. Koh, M.D.
MORE►
Illustration: LanternPharma
Lantern Pharma Adds VP of Clinical Development, Additional Team Members
by Lance Murray | Mar 2, 2023
Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members.
Lantern Pharma is a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development....
MORE►
by Lance Murray |
Feb 15, 2023
Dallas-based Financial Strategies Acquisition Corp. has acquired Texas-based preclinical pharmaceutical company Austin Biosciences Corp.
Financial Strategies is a special purpose acquisition company led by CEO Alexander V. Schinzing. It said that upon the deal’s closing, Austin Biosciences will become a wholly owned subsidiary of the company.
Earlier this month, Financial Strategies announced that its board approved an extension of the period of time available to consummate the deal by one month from Feb....
MORE►
by Kevin Cummings |
Jun 23, 2022
Two giants in their industry are teaming up to accelerate cancer research. The new joint venture is an "important step forward" to increase access to clinical trials, says McKesson CEO Brian Tyler, McKesson CEO.
Separate from the joint venture deal, McKesson will acquire Genospace, a personalized precision medicine platform that’s part of HCA’s research institute.
MORE►
by Kevin Cummings |
Jun 2, 2022
Instead of shipping a patient's blood to a lab for customized cell therapy, Lupagen does the procedure "in vivo," using a dialysis-like treatment at the patient's bedside. Now it's collaborating with Umoja Biopharma to use its drug-delivery tech to place targeted immunotherapies in patients.
“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."
“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."
MORE►
OncoNano CEO Martin Driscoll [Photo: OncoNano]
Southlake Biotech OncoNano Medicine Raises $50M in Series B to Accelerate Cancer Tech Toward Commercialization
by Alex Edwards | Jun 17, 2021
The investment was led by Advantech Capital, a PE fund based in China that focuses on TMT, pharmaceuticals, and healthcare. This combined with the support from the Cancer Prevention and Research Institute of Texas (CPRIT), which granted OncoNano $9.97 million last year, will support Phase 3 clinical trials for the biotech's technology that can diagnose and treat cancer with high specificity.
MORE►
by Alex Edwards |
Jun 8, 2021
Dallas' Mary Kay Foundation has donated $150,000 to CancerCare to provide direct support to women who are most in need of financial or emotional assistance.
MORE►
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
by Alex Edwards |
Oct 15, 2020
The novel invention from researchers at Texas Woman’s University in Denton could greatly contribute to cancer treatment research. The compounds can prevent the growth of breast, lung, and colon cancer cells.
MORE►
[Photo: vitanovski via iStock]
Caris Life Sciences Launches AI-Driven Profiling Tool for Tumors
by Lance Murray | Dec 12, 2019
The Genomic Profiling Similarity Score uses over 6,500 mathematical models in a machine learning algorithm to compare molecular characteristics of a patient's tumor against Caris' extensive database.
MORE►
by Lance Murray |
Dec 6, 2019
In this weekly roundup of research and development activity in North Texas, you’ll also read about how Caris Life Sciences is offering a new tool to evaluate hereditary cancer risks.
MORE►
by Lance Murray |
Oct 7, 2019
This alum of Dallas startup accelerator Health Wildcatters is working with the National Cancer Institute's Developmental Therapeutics Branch on precision research and treatments.
MORE►
by Lance Murray |
Sep 6, 2019
In this weekly roundup of research and development activity in North Texas, you’ll also find how work involving a UT Arlington professor's research shows promise in treating deep-seated tumors.
MORE►
